头孢噻肟与丙种球蛋白配合对新生儿败血症的PCT、CRP、CD55及临床疗效的影响

戴秀凤

[摘要] 目的 探討头孢噻肟联合丙种球蛋白治疗新生儿败血症的临床疗效及对PCT、CRP、CD55的影响。方法 方便选取该院2016年1月—2019年1月收治的新生儿败血症患儿76例，根据不同治疗方法分为两组，对照组（n=38）接受头孢噻肟治疗，观察组（n=38）在对照组基础上接受丙种球蛋白治疗，对比两组患儿治疗前后血清学指标和临床症状改善时间、住院时间、血培养转阴率、临床疗效。结果 治疗后观察组患儿PCT、CRP、CD55水平分别为（1.77±0.44）ng/L、（11.52±4.31）mg/L、（31.47±12.47）MFI，对照组分别为（3.30±1.51）ng/L、（16.54±3.56）mg/L、（43.54±13.54）MFI，观察组显著低于对照组，差异有统计学意义（t=5.997、5.536、4.042，P<0.05）。观察组体温改善时间、神经系统症状改善时间、拒奶改善时间、住院时间分别为（3.6±1.1）d、（6.2±1.7）d、（5.1±2.1）d、（7.6±2.1）d，对照组分别为（6.3±1.3）d、（8.9±1.9）d、（7.7±2.6）d、（11.7±2.8）d，两组患儿对比差异有统计学意义（t=9.774、6.528、4.796、7.221，P<0.05）。两组患儿血培养转阴率对比，观察组血培养转阴率86.84%（33/38）显著高于对照组57.89%（22/38），差异有统计学意义（χ2=20.955，P<0.05）。两组患者临床疗效对比，观察组总有效率89.47%（34/38）显著优于对照组71.05%（27/38），差异有统计学意义（χ2=10.708，P<0.05）。 结论 头孢噻肟联合丙种球蛋白可有效改善血清学指标和临床症状，促进血培养转阴，提高临床疗效，缩短住院时间，值得临床推广。

[关键词] 头孢噻肟;丙种球蛋白;新生儿

[中图分类号] R985          [文献标识码] A          [文章编号] 1674-0742（2020）01（b）-0088-03

Effects of Cefotaxime Combined with Gamma Globulin on PCT， CRP， CD55 and Clinical Efficacy of Neonatal Sepsis

DAI Xiu-feng

Department of Neonatology， Guanxian Central Hospital， Guanxian， Shandong Province， 252500 China

[Abstract] Objective To investigate the clinical efficacy of cefotaxime combined with gamma globulin in the treatment of neonatal sepsis and its effects on PCT， CRP and CD55. Methods 76 children with neonatal sepsis admitted convenient to the hospital from January 2016 to January 2019 were divided into two groups according to different treatment methods. The control group （n=38） received cefotaxime treatment， and the observation group （ n=38） on the basis of the control group， gamma globulin was treated. The serum and clinical symptoms improvement time， hospitalization time， blood culture conversion rate and clinical efficacy were compared before and after treatment. Results The levels of PCT， CRP and CD55 in the observation group were （1.77±0.44）ng/L， （11.52±4.31）mg/L and （31.47±12.47） MFI， respectively， and the control group was （3.30±1.51） ng/L， （16.54±3.56）mg/L， and （43.54±13.54）MFI were significantly lower in the observation group than in the control group，the difference was statistically significant（t=5.997， 5.536， 4.042， P<0.05）. The improvement time of body temperature， time of improvement of nervous system symptoms， time of improvement of milk rejection， and hospitalization time were （3.6±1.1）d， （6.2±1.7）d， （5.1±2.1）d，（7.6±2.1）d， respectively， and the control group was（6.3±1.3）d. （8.9±1.9）d， （7.7±2.6）d， （11.7±2.8）d， the difference between the two groups was statistically significant （t=9.774， 6.528， 4.796， 7.221， P<0.05）. The blood culture conversion rate of the two groups was significantly different. The blood culture conversion rate of the observation group was 86.84% （33/38）， which was significantly higher than that of the control group 57.89% （22/38）， the difference was statistically significant （χ2=20.955， P<0.05）. The clinical efficacy of the two groups was significantly different. The total effective rate of the observation group was 89.47% （34/38）， which was significantly better than that of the control group 71.05%， （27/38）， the difference was statistically significant （χ2=10.708， P<0.05）. Conclusion Cefotaxime combined with gamma globulin can effectively improve serum markers and clinical symptoms， promote blood culture， reduce clinical efficacy， shorten hospitalization time， and is worthy of clinical promotion.